These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 25531586)

  • 21. 25 years of small molecular weight kinase inhibitors: potentials and limitations.
    Fabbro D
    Mol Pharmacol; 2015 May; 87(5):766-75. PubMed ID: 25549667
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.
    Cox KJ; Shomin CD; Ghosh I
    Future Med Chem; 2011 Jan; 3(1):29-43. PubMed ID: 21428824
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A structural atlas of kinases inhibited by clinically approved drugs.
    Wang Q; Zorn JA; Kuriyan J
    Methods Enzymol; 2014; 548():23-67. PubMed ID: 25399641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inverse in silico-in vitro fishing of unexpected paroxetine kinase targets from tumor druggable kinome.
    Zhou W; Yang H; Wang H
    J Mol Model; 2020 Jul; 26(8):197. PubMed ID: 32623519
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.
    Fang Z; Grütter C; Rauh D
    ACS Chem Biol; 2013 Jan; 8(1):58-70. PubMed ID: 23249378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel kinase inhibitors by reshuffling ligand functionalities across the human kinome.
    Vidović D; Muskal SM; Schürer SC
    J Chem Inf Model; 2012 Dec; 52(12):3107-15. PubMed ID: 23121521
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dual Kinase-Bromodomain Inhibitors in Anticancer Drug Discovery: A Structural and Pharmacological Perspective.
    Carlino L; Rastelli G
    J Med Chem; 2016 Oct; 59(20):9305-9320. PubMed ID: 27559828
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein kinase inhibitors: insights into drug design from structure.
    Noble ME; Endicott JA; Johnson LN
    Science; 2004 Mar; 303(5665):1800-5. PubMed ID: 15031492
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bivalent inhibitors of protein kinases.
    Gower CM; Chang ME; Maly DJ
    Crit Rev Biochem Mol Biol; 2014; 49(2):102-15. PubMed ID: 24564382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Structural biology contributions to tyrosine kinase drug discovery.
    Cowan-Jacob SW; Möbitz H; Fabbro D
    Curr Opin Cell Biol; 2009 Apr; 21(2):280-7. PubMed ID: 19208462
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Small molecule kinase inhibitors as anti-cancer therapeutics.
    Chahrour O; Cairns D; Omran Z
    Mini Rev Med Chem; 2012 May; 12(5):399-411. PubMed ID: 22303944
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New insights in protein kinase conformational dynamics.
    Saladino G; Gervasio FL
    Curr Top Med Chem; 2012; 12(17):1889-95. PubMed ID: 23116468
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Blocking the mTOR pathway: a drug discovery perspective.
    Garcia-Echeverria C
    Biochem Soc Trans; 2011 Apr; 39(2):451-5. PubMed ID: 21428918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of Free-Wilson selectivity analysis for combinatorial library design.
    Sciabola S; Stanton RV; Johnson TL; Xi H
    Methods Mol Biol; 2011; 685():91-109. PubMed ID: 20981520
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A new paradigm for protein kinase inhibition: blocking phosphorylation without directly targeting ATP binding.
    Bogoyevitch MA; Fairlie DP
    Drug Discov Today; 2007 Aug; 12(15-16):622-33. PubMed ID: 17706543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding.
    Sheinerman FB; Giraud E; Laoui A
    J Mol Biol; 2005 Oct; 352(5):1134-56. PubMed ID: 16139843
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A quantitative analysis of kinase inhibitor selectivity.
    Karaman MW; Herrgard S; Treiber DK; Gallant P; Atteridge CE; Campbell BT; Chan KW; Ciceri P; Davis MI; Edeen PT; Faraoni R; Floyd M; Hunt JP; Lockhart DJ; Milanov ZV; Morrison MJ; Pallares G; Patel HK; Pritchard S; Wodicka LM; Zarrinkar PP
    Nat Biotechnol; 2008 Jan; 26(1):127-32. PubMed ID: 18183025
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Computational proteomics of biomolecular interactions in the sequence and structure space of the tyrosine kinome: deciphering the molecular basis of the kinase inhibitors selectivity.
    Verkhivker GM
    Proteins; 2007 Mar; 66(4):912-29. PubMed ID: 17173284
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced molecular dynamics simulation methods for kinase drug discovery.
    Aci-Sèche S; Ziada S; Braka A; Arora R; Bonnet P
    Future Med Chem; 2016 Apr; 8(5):545-66. PubMed ID: 27054816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Direct small-molecule kinase activation: Novel approaches for a new era of drug discovery.
    Simpson GL; Hughes JA; Washio Y; Bertrand SM
    Curr Opin Drug Discov Devel; 2009 Sep; 12(5):585-96. PubMed ID: 19736618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.